Latest Antiviral Products News

Zoono Group is seeking up to A$1.61 million from a non-renounceable rights issue after completing a separate A$250,000 placement, with its offer document warning of material uncertainty around going concern. The funds are intended to support shelf-life extension projects, intellectual property and working capital, but investors face dilution and an unresolved legal case.

Argent BioPharma has secured exclusive commercialisation rights to selected Tollovir, Tollovid and NutraVir antiviral products in a worldwide deal excluding China. The agreement adds a new commercial pillar alongside CimetrA®, but does not itself grant pharmaceutical development rights or establish clinical efficacy.